Supporting data for "SARS-CoV-2: Immune Response Elicited by Vaccines and Infection"

The COVID-19 pandemic highlighted the critical role of vaccines in reducing morbidity and mortality. However, vaccine efficacy is influenced by host-specific factors, waning immunity, and the emergence of immune-evasive viral variants. This thesis investigates these dynamics through four independent cohort studies, evaluating the immunogenicity, durability, and real-world performance of the BNT162b2 (mRNA) and CoronaVac (inactivated virus) vaccines, along with booster regimens.The cohorts included (1) a primary vaccination cohort for longitudinal profiling of antibody responses; (2) Hospitalized patient cohort to study post-vaccination infections; and (3) an updated vaccine booster cohort to assess XBB.1.5 mRNA boosting.We methodologically employed iFlash RBD-neutralizing antibody (NAb) assays, iFlash-SARS-CoV-2 IgG-S assay, live virus microneutralization (vMN), and intracellular cytokine staining to comprehensively profile humoral and cellular immune responses against SARS-CoV-2 variants.